# Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)

> **NCT03289273** · — · COMPLETED · sponsor: **Bayer** · enrollment: 1010 (actual)

## Conditions studied

- Liver Neoplasms

## Interventions

- **DRUG:** Regorafenib (Stivarga, BAY73-4506)

## Key facts

- **NCT ID:** NCT03289273
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-13
- **Primary completion:** 2022-01-31
- **Final completion:** 2022-06-21
- **Target enrollment:** 1010 (ACTUAL)
- **Last updated:** 2023-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03289273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03289273, "Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03289273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*